Published in Proc Natl Acad Sci U S A on February 03, 1998
Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med (2004) 1.72
Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol Cell Biol (2002) 1.67
Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol (2000) 1.38
Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res (2009) 1.35
TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med (1998) 1.34
Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest (1998) 1.23
The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol (2000) 1.22
Proinflammatory consequences of transgenic fas ligand expression in the heart. J Clin Invest (2000) 1.03
Bax-mediated cell death by the Gax homeoprotein requires mitogen activation but is independent of cell cycle activity. EMBO J (1998) 0.90
TGF-β/Smad3 inhibit vascular smooth muscle cell apoptosis through an autocrine signaling mechanism involving VEGF-A. Cell Death Dis (2014) 0.86
Defective Fas Expression on Bone Marrow Derived Cells Alters Atherosclerotic Plaque Morphology in Hyperlipidemic Mice. Discoveries (Craiova) (2015) 0.78
Iroquois homeobox transcription factor (Irx5) promotes G1/S-phase transition in vascular smooth muscle cells by CDK2-dependent activation. Am J Physiol Cell Physiol (2016) 0.76
Human interleukin-10 gene inhibits acute rejection by triggering apoptosis in allograft vascular transplantation. Int J Clin Exp Pathol (2014) 0.75
The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 27.07
The Fas death factor. Science (1995) 13.81
Lethal effect of the anti-Fas antibody in mice. Nature (1993) 9.20
Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (1995) 8.23
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A (1994) 8.13
A role for CD95 ligand in preventing graft rejection. Nature (1995) 6.07
Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest (1983) 6.05
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 6.02
Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med (1996) 5.09
Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet (1994) 4.40
A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med (1995) 4.30
Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell (1993) 3.47
Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science (1996) 3.35
Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med (1997) 3.03
Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science (1994) 2.79
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 2.73
Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest (1991) 2.70
Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol (1996) 2.14
Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol (1991) 2.03
Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A (1993) 1.94
Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation (1997) 1.91
Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest (1992) 1.82
Antitumor effect of locally produced CD95 ligand. Nat Med (1997) 1.82
The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol (1992) 1.79
Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science (1995) 1.77
p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev (1997) 1.63
Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest (1997) 1.57
Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. Circulation (1997) 1.57
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest (1997) 1.43
Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J Exp Med (1994) 1.43
Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol (1992) 1.41
Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation (1997) 1.36
Rb functions to inhibit apoptosis during myocyte differentiation. Cancer Res (1997) 1.35
In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci U S A (1994) 1.29
Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest (1995) 1.29
Endothelial cell behavior after denudation injury is modulated by transforming growth factor-beta1 and fibronectin. Lab Invest (1989) 1.28
Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest (1995) 1.23
Defective neutrophil function in the autoimmune mouse strain MRL/lpr. Potential role of transforming growth factor-beta. J Immunol (1991) 1.14
Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol (1995) 1.12
CD95 ligand in graft rejection. Nature (1996) 1.09
Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res (1997) 1.07
Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension (1996) 1.05
Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest (1996) 1.01
Histochemical staining following LacZ gene transfer underestimates transfection efficiency. Hum Gene Ther (1997) 0.98
Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after Systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Hum Gene Ther (1997) 0.92
Enhancer stimulation unmasks latent gene transfer after adenovirus-mediated gene delivery into human vascular smooth muscle cells. Circ Res (1996) 0.86
Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 30.27
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 17.70
Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature (1999) 11.37
Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res (1999) 11.32
Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med (1999) 10.16
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 9.12
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature (1985) 8.23
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J (1999) 6.62
Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A (2000) 6.59
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest (1998) 5.95
The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med (2000) 5.72
Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation (2000) 4.96
Emergence of brown adipocytes in white fat in mice is under genetic control. Effects on body weight and adiposity. J Clin Invest (1998) 4.94
Primary structure and functional expression of the beta 1 subunit of the rat brain sodium channel. Science (1992) 4.44
Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet (1996) 4.32
Mouse model of angiogenesis. Am J Pathol (1998) 4.28
Ore leaching by bacteria. Annu Rev Microbiol (1980) 4.28
Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation (2001) 4.17
Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation (1998) 4.10
The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med (2001) 3.85
Mortality of sea lions along the central California coast linked to a toxic diatom bloom. Nature (2000) 3.82
Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem (1999) 3.76
Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J Cell Biol (1996) 3.71
Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol (2001) 3.66
Mapping point mutations in the Drosophila rosy locus using denaturing gradient gel blots. Genetics (1991) 3.66
Age-dependent impairment of angiogenesis. Circulation (1999) 3.47
MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol (1995) 3.32
Transcatheter occlusion of foramen ovale with a button device after neurological decompression illness in professional divers. Lancet (1996) 3.27
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. J Biol Chem (1983) 2.94
Expression of epidermal growth factor receptors in human brain tumors. Cancer Res (1984) 2.83
Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol (1999) 2.83
Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther (1999) 2.82
Back pain in Britain: comparison of two prevalence surveys at an interval of 10 years. BMJ (2000) 2.73
PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem (2000) 2.57
The branch point effect. Ultrasensitivity and subsensitivity to metabolic control. J Biol Chem (1984) 2.54
Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol (1995) 2.52
Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem (1999) 2.46
Phosphorylation of smooth muscle myosin at two distinct sites by myosin light chain kinase. J Biol Chem (1985) 2.45
Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology (1994) 2.41
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer (2009) 2.39
Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res (2000) 2.39
Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice. Am J Physiol Lung Cell Mol Physiol (2008) 2.30
Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther (2003) 2.29
Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature (1967) 2.29
Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res (1988) 2.28
Thiobacillus acidophilus sp. nov.; isolation and some physiological characteristics. Can J Microbiol (1975) 2.28
The control of protein phosphatase-1 by targetting subunits. The major myosin phosphatase in avian smooth muscle is a novel form of protein phosphatase-1. Eur J Biochem (1992) 2.26
Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation (1998) 2.25
Dietary calcium, physical activity, and risk of hip fracture: a prospective study. BMJ (1989) 2.24
A prospective cytogenetic study of 36 cases of DiGeorge syndrome. Am J Hum Genet (1992) 2.23
Cell cycle exit upon myogenic differentiation. Curr Opin Genet Dev (1997) 2.22
HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest (2001) 2.20
Congenital anomalies in American Indians of British Columbia. Genet Epidemiol (1986) 2.13
Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med (2000) 2.13
Results of balloon pulmonary valvuloplasty as a palliative procedure in tetralogy of Fallot. J Am Coll Cardiol (1991) 2.10
Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol (1994) 2.08
Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages. Role of Mcl-1, independent of nuclear factor (NF)-kappaB, Bad, or caspase activation. J Exp Med (2001) 2.06
Branch point control by the phosphorylation state of isocitrate dehydrogenase. A quantitative examination of fluxes during a regulatory transition. J Biol Chem (1985) 2.06
Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science (1996) 2.03
Two nuclear factors compete for the skeletal muscle actin promoter. J Biol Chem (1987) 2.02
Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res (1995) 1.98
Prenatally diagnosed neural tube defects: ultrasound, chromosome, and autopsy or postnatal findings in 212 cases. Am J Med Genet (1998) 1.94
FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J Exp Med (1999) 1.92
Centenarians: the older you get, the healthier you have been. Lancet (1999) 1.92
Functional antagonism between YY1 and the serum response factor. Mol Cell Biol (1992) 1.91
Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation (1997) 1.91
Determination of flux through the branch point of two metabolic cycles. The tricarboxylic acid cycle and the glyoxylate shunt. J Biol Chem (1984) 1.91
Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood (1996) 1.85
The initial product and properties of the sulfur-oxidizing enzyme of thiobacilli. Biochim Biophys Acta (1966) 1.85
Elf-1 is a transcriptional regulator of the Tie2 gene during vascular development. Circ Res (2001) 1.81
Cell cycle withdrawal promotes myogenic induction of Akt, a positive modulator of myocyte survival. Mol Cell Biol (1999) 1.81
Myosin light chain phosphatase activities and the effects of phosphatase inhibitors in tonic and phasic smooth muscle. J Biol Chem (1992) 1.79
The glycogenolytic response to stimulation of the splanchnic nerves in adrenalectomized calves. J Physiol (1970) 1.77
HIV seroprevalence among homeless patients admitted to a psychiatric inpatient unit. Am J Psychiatry (1993) 1.74
Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol (2000) 1.74
Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis (2003) 1.74
Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest (2001) 1.73
Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene (2006) 1.73
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther (2008) 1.73
Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem (2001) 1.72
Myosin II activation promotes neurite retraction during the action of Rho and Rho-kinase. Genes Cells (1998) 1.71
A novel mechanism for the Ca(2+)-sensitizing effect of protein kinase C on vascular smooth muscle: inhibition of myosin light chain phosphatase. J Gen Physiol (1994) 1.70
Characterization of rate-controlling steps in vivo by use of an adjustable expression vector. Proc Natl Acad Sci U S A (1985) 1.69
ERP, a new member of the ets transcription factor/oncoprotein family: cloning, characterization, and differential expression during B-lymphocyte development. Mol Cell Biol (1994) 1.67
Cloning, chromosomal localization and expression analysis of the mouse Akt2 oncogene. Oncogene (1995) 1.67
Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/- mice. Circulation (1999) 1.66
Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation (1998) 1.65
Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J Biol Chem (2001) 1.65
Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care (1999) 1.65
Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem (2001) 1.64
Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB. J Virol (2000) 1.63
p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev (1997) 1.63
Alkaline phosphatase assay for freshwater sediments: application to perturbed sediment systems. Appl Environ Microbiol (1979) 1.62